Novo Nordisk A/S (NVO) Stock Price Quote, News & Filings

Summary

Novo Nordisk A/S operates as a prominent global pharmaceutical firm, dedicated to the discovery, development, production, and distribution of a wide array of medicinal products. Its extensive operations are primarily structured into two distinct divisions: Diabetes and Obesity Care, and Biopharmaceuticals. The Diabetes and Obesity Care segment offers comprehensive solutions, encompassing various insulin preparations, GLP-1 receptor agonists along with their delivery systems, oral antidiabetic medications, treatments for weight management, and therapies addressing other chronic health conditions. Meanwhile, the Biopharmaceuticals division is focused on specialized treatments for hemophilia, growth hormone disorders, and hormone replacement therapy. The company actively engages in strategic collaborations, notably including an agreement with Gilead Sciences, Inc. Furthermore, Novo Nordisk A/S is engaged in a research partnership with Lumen Bioscience, Inc., aiming to explore innovative methods for administering oral biologics for the management of cardiometabolic diseases. Established in 1923, the company's main corporate offices are located in Bagsvaerd, Denmark.

Website

www.novonordisk.com

Location

Bagsvaerd, G7, DK

Phone45 44 44 88 88

Employees68,794

CEOMaziar Mike Doustdar

Sector

Health Care

Industry

Pharmaceuticals

IPO DateApr 30, 1981

Ask AI

Company overview

Business model, segments, and competition.

Peer comparison

Metrics vs closest competitors.

Guidance & outlook

Forward guidance and assumptions.

Bull vs bear case

Upside drivers and key risks.

Valuation snapshot

Multiples vs history and peers.

Competitive moat

Defensibility and market position.

Management track record

Leadership and capital allocation history.

How it makes money

A short diagram of the business model.

Latest Documents

Mentions in Filings

Other than the rights we have granted to Eyconis, Inc. (“Eyconis”), Teijin, and VISEN as noted in this report, and rights previously granted to Novo Nordisk A/S (“Novo Nordisk”) in metabolic and cardiovascular diseases that will revert to us upon effective termination of our collaboration agreement, we hold worldwide rights to our TransCon technologies. Other than our royalty financing arrangements with Royalty Pharma and our royalty obligations …
Ascendis Pharma A/SNovo Nordisk A/S·6-K - Current report (foreign private issuer)·Q3 26·12 Nov
… be able to capitalize on the market potential of these product candidates and our business could be adversely affected. 5 --- • If we fail to comply with our obligations under our existing license agreements with Novo Nordisk A/S and Genmab A/S, or under any future intellectual property licenses, or otherwise experience disruptions to our business relationships with our current or any future licensors, we could lose intellectual property righ …
Hemab Therapeutics Holdings, Inc.Novo Nordisk A/S·10-Q - Quarterly report Q3·Q3 26·10 Nov
On February 9, 2026, Novo Nordisk A/S and Novo Nordisk Inc. (together, “Novo Nordisk”) filed a lawsuit in the U.S. District Court for the District of Delaware captioned Novo Nordisk A/S, et al. v. Hims & Hers Health, Inc., et al., No. 1:26-cv-0014. The complaint asserts claims for patent infringement related to Novo Nordisk’s U.S. Patent No. 8,129,343 (the “‘343” patent) in connection with compounded GLP-1 products containing semaglutide availabl …
Hims & Hers Health, Inc.Novo Nordisk A/S·10-Q - Quarterly report Q3·Q3 26·9 Nov
… grams to further develop our pipeline; • the ability of our preclinical studies and clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results; • the partnership with Novo Nordisk A/S (“Novo”) and the intended and potential benefits thereof, including the receipt of potential milestone and royalty payments from commercial product sales, along with tiered royalties based on global net sales, if any
Septerna, Inc.Novo Nordisk A/S·10-Q - Quarterly report Q3·Q3 26·9 Nov
… MENT NO. 1 TO COLLABORATION AND LICENSE AGREEMENT This AMENDMENT NO. 1 (this “Amendment”) to the Agreement (as defined below) is entered into as of September 10, 2026 (the “Amendment Effective Date”) by and between Novo Nordisk A/S, a corporation organized and existing under the laws of Denmark, having an address at Novo Nordisk Allé, 2880 Bagsvaerd, Denmark, CVR No. 24 25 67 90 (“Novo Nordisk”), on the one hand, and Septerna, Inc., a Delaware …
Septerna, Inc.Novo Nordisk A/S·EX-10.1 - 10-Q - Quarterly report Q3·Q3 26·9 Nov
… armaceuticals, Inc. Our Chief Medical Officer, Jyothis George, MBBS, Ph.D., brings substantial drug development experience, having held senior clinical, medical and regulatory roles at companies including Amgen Inc., Novo Nordisk A/S, or Novo Nordisk, and Boehringer Ingelheim Pharmaceuticals, Inc. Our founder and Chief Scientific Officer, Alan P. Watt, Ph.D., M.B.A., brings substantial research, discovery, nonclinical and translational experience …
Rezera Inc.Novo Nordisk A/S·S-1/A - Registration statement (general form, amendment)·Q4 26·9 Nov

Key Stats

Trading

Px/Chg 1D$37.32 / -0.21%

Avg Volume18.12M

Beta0.92

Mkt Cap165.72B

FD Mkt Cap201.58B

Float

Shrs Out/Float4.44B / 3.17B

Short Float0.01%

Days to Cover2.20

Stock Repurchased$2.40B

Current Valuation

EV290.98B

EV/EBITDA1.57

EV/Sales0.89

P/B0.82

P/S0.51

FCF Yield7.27%

ROE23.91%

ROA8.68%

Current Ratio0.79

Dividend

Cash$1.22

Yield5.11%

Yield (TTM)5.11%

Estimates

P/E1.36

Est P/E0.00

Est EPS0.87

Est PEG0.00

Valuation

Metric	5Yr Avg	Mar '23	Mar '24	May '25	May '26	Oct '26
PRICE-BASED RATIOS
Price / Earnings	5.42	6.45	6.88	2.92	7.42	3.41
Price / Sales	1.95	2.02	2.48	1.02	2.52	1.71
Price / Book Value	2.72	4.29	5.40	2.06	1.03	0.82
Price / Free Cash Flow	5.26	5.58	8.22	4.24	-5.51	13.76
ENTERPRISE VALUE METRICS
Enterprise Value	387,381.8	371,274.9	588,205.5	382,381.0	304,069.1	290,978.5
Enterprise Value / Sales	2.56	2.10	2.53	1.32	3.84	3.01
Enterprise Value / EBITDA	4.88	4.83	5.13	2.58	7.65	4.20
Enterprise Value / EBIT	5.45	5.35	5.59	2.97	8.89	4.43

Financials

Full Financials

Millions DKK	5Yr CAGR (%)	Dec '21	Dec '22	Dec '23	Dec '24	Dec '25
INCOME STATEMENT
Revenue	21.7%	140,800.0	176,954.0	232,261.0	290,403.0	309,064.0
Gross Income	20.9%	117,142.0	148,506.0	196,496.0	245,881.0	250,276.0
EBITDA	24.4%	65,394.0	76,802.0	114,629.0	147,938.0	156,729.0
EBIT	22.7%	59,369.0	69,440.0	105,216.0	128,831.0	134,747.0
Net Income	21%	47,757.0	55,525.0	83,683.0	100,988.0	102,434.0
EPS (Diluted)	22.1%	10.37	12.22	18.62	22.63	23.03
BALANCE SHEET
Cash & ST Inv	11.4%	17,485.0	23,574.0	30,230.0	26,308.0	26,962.0
Total Assets	29.3%	194,508.0	241,257.0	314,486.0	465,795.0	542,902.0
Total Liabilities	29.6%	123,762.0	157,771.0	207,925.0	322,309.0	348,855.0
Total Shareholder Equity	28.7%	70,746.0	83,486.0	106,561.0	143,486.0	194,047.0
CASH FLOW
Net Operating Cash Flow	21.3%	55,000.0	78,887.0	108,908.0	120,968.0	119,102.0
Cap Ex	86.9%	-7,385.0	-14,753.0	-38,896.0	-51,309.0	-90,113.0
Free Cash Flow	-11.7%	47,615.0	64,134.0	70,012.0	69,659.0	28,989.0

Enterprise Value Bridge

Millions DKK		13 Nov '26
Price (As of 13 Nov '26)		41.65
Basic Shares		4,440.61
Market Cap		184,929.1
Diluted Shares		4,422.90
Fully Diluted Shares Outstanding		4,422.90
Fully Diluted Market Cap		184,191.7
+Consolidated Debt		134,480.0
−In-the-Money Convertible Debt		—
+Capital Leases		-
+Operating Leases		—
−Cash & Equivalents		-44,151.0
−Short-term Investments		-5,025.0
+Total Preferred		-
−In-the-Money Convertible Preferred		—
−Investments in Unconsolidated Subs		—
+Non-Controlling Interest		-
+Pension Liabilities		—
Enterprise Value		275,258.1

Segment data

Revenue

by Geography

North America63%
Emea24%
Rest Of World13%

Related companies